A simpler diabetes tech is in the offing, but some patients are yet to be convinced that a device knows best.
New devices are coming, but the real advances will involve combinations.
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.